

Interpreting Genetic Variants in Titin in Patients With Muscle Disorders

Marco Savarese, PhD; Lorenzo Maggi, MD; Anna Vihola, PhD; Per Harald Jonson, PhD; Giorgio Tasca, MD; Lucia Ruggiero, MD; Luca Bello, MD; Francesca Magri, MD; Teresa Giugliano, PhD; Annalaura Torella, PhD; Anni Evilä, PhD; Giuseppina Di Fruscio, PhD; Olivier Vanakker, MD; Sara Gibertini, PhD; Liliana Vercelli, MD; Alessandra Ruggieri, PhD; Carlo Antozzi, MD; Helena Luque, BSc; Sandra Janssens, MD; Maria Barbara Pasanisi, MD; Chiara Fiorillo, MD; Monika Raimondi, MD; Manuela Ergoli, MSc; Luisa Politano, MD; Claudio Bruno, MD; Anna Rubegni, MD; Marika Pane, MD; Filippo M. Santorelli, MD; Carlo Minetti, MD; Corrado Angelini, MD; Jan De Bleecker, MD; Maurizio Moggio, MD; Tiziana Mongini, MD; Giacomo Pietro Comi, MD; Lucio Santoro, MD; Eugenio Mercuri, MD; Elena Pegoraro, MD; Marina Mora, PhD; Peter Hackman, PhD; Bjarne Udd, MD; Vincenzo Nigro, MD

IMPORTANCE Mutations in the titin gene (*TTN*) cause a wide spectrum of genetic diseases. The interpretation of the numerous rare variants identified in *TTN* is a difficult challenge given its large size.

OBJECTIVE To identify genetic variants in titin in a cohort of patients with muscle disorders.

DESIGN, SETTING, AND PARTICIPANTS In this case series, 9 patients with titinopathy and 4 other patients with possibly disease-causing variants in *TTN* were identified. Titin mutations were detected through targeted resequencing performed on DNA from 504 patients with muscular dystrophy, congenital myopathy, or other skeletal muscle disorders. Patients were enrolled from 10 clinical centers in April 2012 to December 2013. All of them had not received a diagnosis after undergoing an extensive investigation, including Sanger sequencing of candidate genes. The data analysis was performed between September 2013 and January 2017. Sequencing data were analyzed using an internal custom bioinformatics pipeline.

MAIN OUTCOMES AND MEASURES The identification of novel mutations in the *TTN* gene and novel patients with titinopathy. We performed an evaluation of putative causative variants in the *TTN* gene, combining genetic, clinical, and imaging data with messenger RNA and/or protein studies.

RESULTS Of the 9 novel patients with titinopathy, 5 (55.5%) were men and the mean (SD) age at onset was 25 (15.8) years (range, 0-46 years). Of the 4 other patients (3 men and 1 woman) with possibly disease-causing *TTN* variants, 2 (50%) had a congenital myopathy and 2 (50%) had a slowly progressive distal myopathy with onset in the second decade. Most of the identified mutations were previously unreported. However, all the variants, even the already described mutations, require careful clinical and molecular evaluation of probands and relatives. Heterozygous truncating variants or unique missense changes are not sufficient to make a diagnosis of titinopathy.

CONCLUSIONS AND RELEVANCE The interpretation of *TTN* variants often requires further analyses, including a comprehensive evaluation of the clinical phenotype (deep phenotyping) as well as messenger RNA and protein studies. We propose a specific workflow for the clinical interpretation of genetic findings in titin.

JAMA Neurol. doi:10.1001/jamaneurol.2017.4899
Published online February 12, 2018.

← Editorial

+ Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Marco Savarese, PhD, Folkhälsan Research Center, Medicum, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland (marco.savarese@helsinki.fi).

The *TTN* gene encodes titin, a giant sarcomeric protein, spanning from the Z-disc to the M-band.¹ Titin plays crucial functional and structural roles in the sarcomere.² Mutations in the *TTN* gene cause several different muscle disorders, cardiomyopathies, and combinations of these.^{3,4}

The skeletal muscle diseases caused by *TTN* mutations include a wide spectrum of disorders.⁵ The late-onset autosomal dominant tibial muscular dystrophy (TMD) is caused by mutations in the last exon (364), which cause a posttranslational pathological cleavage of a larger portion of the C-terminal titin protein.⁶⁻⁸

Young- or early-adult-onset recessive distal titinopathy is due to either 2 mutations in the last 2 exons (363-364), or 1 mutation in these exons and a truncating mutation on the other allele.⁹ Similarly, 2 C-terminal mutations or 1 C-terminal mutation along with a truncating variant in trans cause an early-onset recessive limb-girdle muscular dystrophy 2J.¹⁰⁻¹²

Other congenital or early-onset recessive titinopathies comprise disorders with heterogeneous clinical and histological features: congenital centronuclear myopathy,^{13,14} early-onset myopathy with fatal cardiomyopathy,¹⁵ multimincore disease with heart disease,¹⁶ and childhood-juvenile-onset Emery-Dreifuss-like myopathy phenotype without cardiomyopathy.¹⁷ Hereditary myopathy with early respiratory failure (HMERF) represents an increasingly identified, completely different adult-onset myopathy, mainly because of dominant mutations in exon 344.¹⁸

Many additional *TTN*-related muscular phenotypes are emerging as a consequence of next-generation sequencing (NGS) screening in patients with myopathy.⁵ For instance, adult-onset proximal lower limb weakness without ankle dorsiflexion weakness has been described in 2 unrelated patients who had a TMD-causing mutation combined with a second missense mutation.^{9,19} Recently, a novel *TTN* homozygous truncating mutation was found in a patient with arthrogryposis multiplex congenita and severe axial hypotonia as a form of congenital amyoplasia without cardiac involvement.²⁰ The mutation occurs within an exon, which seems to be expressed only in the fetal skeletal isoform.²⁰

Next-generation sequencing is rapidly being implemented into routine clinical practice, improving the diagnostic rate for patients with neuromuscular diseases.²¹⁻²³ Almost all NGS screenings reveal many rare and private titin variants and their clinical interpretation is particularly challenging.^{5,19,24-26} By using MotorPlex (Agilent Technologies), a targeted NGS panel, we screened *TTN* and the other muscle disease genes in 504 patients with skeletal muscle disorders.^{25,26} Here, we describe the approach used for the NGS data interpretation and we propose a workflow for a more straightforward and reproducible interpretation of the clinical meaning of titin variants.

Methods

Patients

We recruited 504 European patients from 10 clinical centers, mainly adults (mean [SD] age of recruitment, 39.04 [19.09]

Key Points

Question How can we interpret the variants identified in titin and distinguish the pathogenic from the benign?

Findings In this case series, 504 patients with skeletal muscle disorders were screened with a targeted resequencing approach. An evaluation of titin gene variants that combined genetic, clinical, and imaging data with messenger RNA and/or protein studies identified 9 patients with a titinopathy and 4 patients with possible titinopathy.

Meaning The clinical interpretation of titin gene variants is challenging and requires comprehensive analyses. A specific workflow for the clinical interpretation of genetic findings in titin is suggested.

years) with skeletal muscle disorders. The patients had not received diagnoses despite extensive diagnostic investigations performed according to the observed phenotype. All the patients or their legal guardians provided written informed consent. The study, approved by the ethics committee of the Università della Campania “Luigi Vanvitelli,” was performed in accordance with the Declaration of Helsinki.

Molecular Analysis

Genomic DNA was extracted from the peripheral blood by phenol/chloroform purification. Next-generation sequencing libraries were prepared using MotorPlex, as previously described.^{25,26} An in-house pipeline²⁵⁻²⁷ was used to analyze the raw data.

We focused on patients with previously reported *TTN* mutations or with at least a single *TTN* truncating variant. Missense variants were explicitly studied in a single large recessive family only (family X). Further possible causative variants in genes other than titin were ruled out by a segregation analysis.

Titin gene mutated exons were amplified by polymerase chain reaction using M13-tailed primers. M13 primers were used to perform Sanger sequencing using an ABI PRISM 3130XL Genetic Analyzer (Applied Biosystems).

Direct-zol RNA MiniPrep Kit (Zymo Research) was used to extract RNA from muscle biopsies. Complementary DNA (cDNA) synthesis was performed using RevertAid H Minus Reverse Transcriptase (Thermo Scientific). Reverse-transcription polymerase chain reactions were performed using primers designed with Primer3 software and a DreamTaq DNA Polymerase (Thermo Scientific). Copy number variant analysis was performed using a custom array-comparative genomic hybridization, MotorChip²⁸ (Agilent Technologies). Sequence variants in *TTN* are described according to the coding DNA reference sequence (LRG_391t1), covering transcript variant-IC (NM_001267550.1).

An in silico analysis of missense variants and the prediction of their deleterious effects were performed by homology modeling in DeepView/Swiss-PdbViewer, version 4.1.0 (GlaxoSmithKline R&D and Swiss Institute of Bioinformatics)²⁹ using the most similar structures available in the Protein Data Bank for each titin domain. For titin domains A168 to A170, the

crystal structure is available (2NZI).³⁰ The models were visualized using POV-Ray, version 3.7 (Persistence of Vision Raytracer Pty Ltd); (<http://www.povray.org>).

Muscle Imaging, Histological Studies, and Western Blot Analysis

Muscle magnetic resonance imaging of the lower limbs using 1.5-T magnetic resonance scanners (Siemens and Philips)³¹ and histological and histochemical examinations in muscle biopsies followed standard procedures.³² Western blotting (WB) of muscle biopsy samples was performed according to standard methods.⁹ Two previously described in-house-generated antibodies (rabbit polyclonal antibody M10-1¹¹ and mouse monoclonal antibody 11-4-3⁹) were used to detect the titin M10 domain, followed by horseradish peroxidase-conjugated secondary antibodies (Dako) and enhanced chemiluminescent detection using the Pierce SuperSignal West Femto substrate (Thermo Fisher).⁹

Results

In an extensive study of 504 mainly adult, patients who had not received a genetic diagnosis and were presenting with clinical signs of muscular dystrophy, congenital myopathy, or other skeletal muscle disorders, we identified 9 novel patients (1.8%) with titinopathy and 4 patients (0.8%) with very likely disease-causing *TTN* mutations. The clinical details of each patient are summarized in **Table 1** and described in the eAppendix in the **Supplement**.

Patients With Previously Described Mutations

We identified disease-associated mutations in the *TTN* gene in 3 patients (0.6%). The most common mutation responsible for the HMERF phenotype (p.Cys31712Arg in exon 344)¹⁸ was identified in 2 cases (I and II).

Patient I was a man in his late 50s with no family history for neuromuscular disorders. He presented with a progressive distal weakness in the lower limbs (onset at 40 years) and a restrictive respiratory insufficiency due to respiratory muscle weakness.

Patient II was a man in his mid-50s presenting with a distal myopathy (onset in his mid-40s with myalgia and exercise intolerance). Although pulmonary function test results were only minimally impaired, muscle biopsy results revealed typical histopathological features seen in HMERF, including cytoplasmic bodies and rimmed vacuoles.

A previously reported TMD mutation (p.Ile35947Asn)³³ was identified in compound heterozygosity with a nonsense mutation in a Belgian woman in her early 40s (patient III). This patient has been described elsewhere.³⁴ In brief, she shows an earlier onset (at 30 years) and a more severe phenotype compared with previously reported patients with TMD who carried the same missense variant in heterozygosity.³³

Patients With Biallelic Protein Truncating Variants

In 4 patients (0.8%), protein truncating variants (PTVs) were identified on both alleles. In a man in his early 30s with healthy parents and siblings (patient IV), we found a splice site vari-

ant (c.107377 + 1G>A in intron 362) on the maternal allele and a nonsense variant (p.Tyr21719* in exon 312) on the paternal allele. Since childhood, the patient had shown mildly progressive generalized muscular weakness. He received a diagnosis of dilated cardiomyopathy without arrhythmias in his late teens. Messenger RNA analyses confirmed the splicing effect of the intronic variant (eFigure in the **Supplement**). Western blotting analyses showed a reduced intensity of small C-terminal titin protein fragments and the presence of an additional band due to the splicing defect (**Figure 1**).

A 34-year-old Belgian patient (patient V) with an unremarkable family history harbored the p.Glu11945Argfs*6 variant in exon 164 and the c.25063 + 1G>A variant in intron 87 in compound heterozygosity. Since childhood, the patient had shown a slowly progressive generalized muscular weakness and gait abnormalities with frequent falling. In silico predictions confirmed that c.25063 + 1G>A would result in a splicing defect. Further messenger RNA and WB analyses were not performed because of the unavailability of muscle tissue.

Two further biallelic PTVs were identified in patient VI (p.Val26358Phefs*4 and p.Gln35879*, the latter recently reported as a Balkan-Middle East founder mutation^{34,35}) and in 2 siblings (cases VIIa and VIIb) (p.Cys9322* and p.Arg35800Glnfs*10).

Patient VI was a woman in her mid-50s presenting in her early 30s with frequent tripping. Her family history was unremarkable. The disease worsened and the patient has required a cane to walk for the last 5 years. Echocardiography results in her early 50s showed mild left ventricular hypokinesia and a mildly reduced ejection fraction (43%).

The index case of family VII was a woman in her early 50s (VIIa), with onset in adulthood (in her early 30s) characterized by walking difficulty and distal lower limb muscle weakness. No signs of respiratory or cardiac involvement were detected at a recent follow-up (2016). Patient VIIb, a sibling, showed similar clinical and histological features.

Patients With a Single Heterozygous Protein Truncating Variant

In 1 additional patient (patient VIII) harboring the heterozygous p.Arg35800Glnfs*10 in exon 363, protein analysis results showed a severe reduction with the C-terminal titin antibodies, indicating truncating mutations on both alleles as previously reported in patients with limb-girdle muscular dystrophy 2J.⁹ No additional variants were detected by MotorPlex, and MotorChip did not reveal any copy number variants. The patient had presented with difficulties in running and Achilles' tendon contractures since the preteen years. The weakness in the lower extremities worsened in the early 30s. No signs of cardiomyopathy were detected on heart ultrasonography.

In family IX, the proband was a teenage boy who presented with hypotonia and congenital torticollis at birth. He had delayed motor milestones, reaching independent walking after the toddler years. He was referred to the neuromuscular unit as a child because of a proximal and distal weakness. The patient, as well as his similarly affected sibling, harbored a single-nucleotide duplication (p.Arg26562Thrfs*12) on the maternal allele. In addition, 2 missense variants were

Table 1. Clinical Summary of Index Patients

Variant	Patient No./Sex/Onset, Age/Current, Age	First Symptom	Muscle Weakness	CK	Muscle Involvement (MRI)	Biopsy Findings	Cardiac Impairment	Genotype (LRG_391)	Titinopathy
Previously reported variants	I/M/early 40s/late 50s	Weakness and toe-walking	Prox UL, prox and dist LL	NA	GM, QD, BF, PSM	Connective increase, necrotic fibers	None	(c.95134T>C p.[Cys31712Arg])	
	II/M/mid-40s/mid-50s	Myalgia and exercise intolerance	Prox and dist LL	2-3X	NA	Cytopl. bodies	None	(c.95134T>C p.[Cys31712Arg])	
	III/F/early 30s/early 40s	Walking difficulties	Dist > prox LL	N	TA, EDL, SOL	Atrophic fibers, FTD	None	(c.107840T>A p.[Ile35947Asn]) + (c.67519C>T p.[Gln22507*])	
Biallelic PTVs	IV/M/child/early 30s	Difficulty in running and toe-walking	Dist UL, prox, and dist LL	10X	AM, BF, SM, GST	Rimmed vacuoles, FTD	DCM	(c.107377 + 1G>A) + (c.65157T>A p.[Tyr21719*])	Confirmed
	V/M/infant/early 30s	Hypotonia	Prox UL, prox, and dist LL	N	GM, QD, RF, BF, TA, SOL, GST	FTD, internal nuclei	None	(c.35828dupA p.[Glu11945Argfs*6]) + (c.25063 + 1G>A)	
	VI/F/early 30s/early 50s	Walking difficulties	Dist LL	2X	NA	FTD, cores	Ventricular hypokinesia and reduced ejection fraction	(c.79072delG p.[Val26358Phefs*4]) + (c.107635C>T p.[Gln35879*])	
	VIIa/F/early 30s/early 50s	Walking difficulties	Dist LL	NA	TA, SOL, GST	FTD, autophagic vacuoles	NA	(c.27966T>A p.[Cys9322*]) + (c.107397dupC p.[Arg35800Glnfs*10])	
	VIIb/F/early 30s/early 60s	Walking difficulties	Dist LL	NA	NA	FTD, autophagic vacuoles	Paroxysmal sinus tachycardias and frequent ventricular extrasystoles	(c.27966T>A p.[Cys9322*]) + (c.107397dupC p.[Arg35800Glnfs*10])	
Monoallelic PTV	VIII/M/preteen/late 40s	Difficulty in running	Pectoralis and LL	2-3X	BF, SM, ST, GM, IP and TA	FTD, internal nuclei	None	(c.107397dupC p.[Arg35800Glnfs*10]) + ?	Possible
	IXa/M/infant/teenage	Hypotonia	Prox and dist UL and LL	N	NA	FTD, minicores	NA	(c.79683dupA p.[Arg26562Thrfs*12]) + (c.94015A>G p.[Thr31339Ala]; c.18970A>C p.[Thr6324Pro])	
	IXb/F/infant/teenage	Hypotonia	Prox and dist UL and LL	N	NA	NA	NA	(c.79683dupA p.[Arg26562Thrfs*12]) + (c.94015A>G p.[Thr31339Ala]; c.18970A>C p.[Thr6324Pro])	
Missense variants	Xa/M/teenage/early 50s	Difficulty in running	Dist > prox LL	N	TA and SOL	FTD, autophagic vacuoles	None	(c.100585T>C p.[Trp33529Arg]) + (c.98390A>G p.[Asn32797Ser])	
	Xb/M/teenage/early 40s	Difficulty in running	Dist>Prox LL	N	TA and SOL	FTD, autophagic vacuoles	None	(c.100585T>C p.[Trp33529Arg]) + (c.98390A>G p.[Asn32797Ser])	

Abbreviations: AM, adductor magnus; BF, biceps femoris; CK, creatine kinase; Cytopl bodies, cytoplasmic bodies; DCM, dilated cardiomyopathy; Dist, distal; EDL, extensor digitorum longus; F, female; FTD, fiber-type disproportion; GM, gluteus maximus; GST, gastrocnemius; IP, iliopsoas; LL, lower limbs; M, male; MRI, magnetic resonance imaging; NA, not available; Prox, proximal; PSM, paraspinal muscles; PTV, protein truncating variant; QD, quadriceps; RF, rectus femoris; SM, semimembranosus; SOL, soleus; ST, semitendinosus; TA, tibialis anterior; UL, upper limbs.

identified on the paternal allele. In particular, a c.18970A>C causing a substitution of a threonine with a proline at position 6324 was identified. The mutated amino acid is located on the external surface of a β strand in an Ig-domain in the I-band region, probably affecting the stability (Figure 2A). The second detected variant was a c.94015A>G leading to a substitution of a threonine at position 31339 with an alanine in an Fn3 domain (A-band portion of titin). The amino acid substitution may affect the interaction with ligands in this region (Figure 2B). A comparative genomic hybridization array ex-


cluded the presence of copy number variants in the proband and WB results showed a reduced intensity of C-terminal M10 fragments (Figure 1B).

Patients With Rare Missense Variants

Because rare missense variants were found in most analyzed patients, we focused on a single recessive family (family X) in whom 2 rare variants segregated with the observed phenotype.

The 2 patients were siblings (mid-40s and mid-50s, respectively) and showed a slowly progressive distal myopathy with

Figure 1. Western Blot for C-terminal Titin Fragments



Western blotting using 2 different antibodies (M10-1 and 11-4-3) against the titin C-terminal M10 domain. A, Patient VIII with a single identified protein truncating variant shows a severe reduction of titin C-terminal fractions of all sizes; patient IV presents a reduced amount of the small (<20 kDa) titin fragments, and additionally the presence of a truncated fragment (arrowheads) resulting from the aberrant splicing due to the splice site mutation in intron 362.

B, Patient Xa with missense mutations showed a normal titin C-terminal pattern, while patient IXa with a single protein truncating variant and 2 missense variants showed a reduction of the small (<20 kDa) titin C-terminal fragments in particular. The myosin heavy chain (MyHC) serves as the loading control. Ctrl indicates control; LGMD2J, limb-girdle muscular dystrophy 2J; TMD, tibial muscular dystrophy.

onset in the second decade. At the latest neurological examination, the patients walked with a waddling gait and bilateral step-gait. Their serum creatine kinase levels were normal. No heart or respiratory involvement was observed. Both siblings harbored 2 compound heterozygous missense variants: p.Asn3279Ser and p.Trp33529Arg. The former is located in an Fn3 domain in the A-band portion of titin, and in silico studies predicted that the amino acid is located on the external surface of the domain, possibly affecting the binding to the interactors. The latter variant is in an Ig-domain, which is located just before Ser/Thr kinase domain (TK). The amino acid change probably affects the folding of the domain (Figure 2). No further clearly or potentially damaging variants were detected by MotorPlex (not even in additional causative or candidate genes) and MotorChip studies did not reveal any causative deletion or duplication. A segregation study confirmed that none of the 3 unaffected siblings were compound heterozygous for these *TTN* missense variants. Western blotting results revealed a normal C-terminal titin pattern, as expected (Figure 1).

Discussion


Because of its size, many rare or private variants are usually identified in the titin gene by NGS analyses.⁵ The correct interpretation of these variants is a critical challenge for making a diagnosis for patients affected by neuromuscular disorders.⁵ Although mainly truncating mutations have been identified in patients with titinopathy, missense variants may similarly have a crucial role, as also suggested by our data (Figure 3).

For the interpretation of genetic findings in *TTN*, we have developed a workflow (Figure 3) based on 3 categories of sequence variants: (1) previously reported mutations, (2) truncating variants, and (3) missense changes and on deep phenotyping (ie, a comprehensive and precise evaluation of phenotypic abnormalities in which each component of the clinical phenotype is observed and described).³⁶ Although the limited number of patients with titinopathy described so far has hampered the identification of specific and unique hallmarks for each *TTN*-related disease, significant key points have been reported (Table 2). The integration of structured clinical data with genetic variations is crucial for a correct evaluation of *TTN* findings, as detailed below.

Previously Reported Mutations

If previously reported disease-causing mutations are identified, they may easily address the diagnosis of a titinopathy; however, segregation studies and a deep phenotyping are mandatory for a correct genotype-phenotype correlation and for proper genetic counselling. In the presence of a previously reported HMERF variant (eg, p.Cys31712Arg), a respiratory involvement and/or the presence of cytoplasmic bodies and myofibrillar changes (seen in patient I and II, respectively) confirm the diagnosis of titinopathy.^{5,18}

The clinical interpretation of mutations in exon 364, previously associated with TMD (like the p.Ile35947Asn in patient III), is more complex. These mutations cause either a dominant, mild, and late-onset distal leg phenotype, or recessive phenotypes.^{7-9,11} Muscle imaging is mandatory and often very informative (Table 2).

Figure 2. Positions of *TTN* Missense Variants Identified in Families IX and X on a Structural Model

All images were made in DeepView/Swiss-PdbViewer, version 4.1.0 (GlaxoSmithKline R&D and Swiss Institute of Bioinformatics). The computed molecular surface is semitransparent gray and the secondary structure is shown with yellow β strands and red α helices. The mutated residue is shown as CPK. A, Position of p.Thr6324Pro using the most similar structure available in the Protein Data Bank (3B43). The mutated residue is located in a β strand. The mutation to proline will induce steric restrictions most probably causing a reduced stability and a structural disruption. B, p.Thr31339Ala modeled using the structure 2NZI of titin domains A168-A170. The change from threonine to alanine is predicted in a loop and will probably not interfere with the structure. However, the hydroxyl group on the sidechain of threonine allows for hydrogen

bonding with other molecules. The amino acid substitution may alter interactions with *TTN* ligands in this specific region. C, Position of p.Asn32797Ser using the structure 2NZI. The mutated amino acid, one of the first residues in the domain, is on the surface of the model and it seems not to cause any important structural change. It will probably affect the binding to the interactors of this domain. D, Position of p.Trp33529Arg using the structure 2JBO. The tryptophan residue p.Trp33529 is almost totally buried in the hydrophobic core of the protein. The change to a positively charged arginine will probably be detrimental for the structural stability and will lead to an unfolding of this domain.

Protein Truncating Variants

Identifying 2 truncating variants in trans results in a diagnosis of titinopathy, which may be corroborated by a WB showing the absence or a severe reduction of the C-terminal protein (patient IV or previously reported patients^{9,34}). However, a complete molecular characterization of variants affecting the canonical or noncanonical splice sites by cDNA or protein studies is suggested.



Biallelic truncating mutations have been so far associated with a wide range of phenotypes, showing heterogeneous clinical and histological features. However, a primary cardiac involvement is often seen and peculiar imaging findings seem to characterize congenital or early onset titinopathies.

Clinically evaluating single heterozygous truncating variants is more complex (Figure 3). Increasing evidence is indi-

cating that titin truncating variants cause recessive skeletal muscle disorders.^{9,15,16,34} In the presence of monoallelic PTVs, we suggest performing a WB analysis that represents the most valuable and potentially conclusive test, as it is the only available tool able to predict the presence of further elusive truncating variants in trans (as seen in patient VIII and in a previously reported patient⁹).

Why are there elusive variants in *TTN*? First, the huge size of the *TTN* gene and its complex structure, due to a 10-kb triplicate region where 9 exons are repeated 3 times, may hamper an exhaustive gene analysis by NGS, resulting in low-covered or noncovered regions and thus in unidentified mutations. Second, additional elusive mutations may be deep intronic or structural variants. Currently available bioinformatics tools³⁷ combined with customized comparative genomic hybridization arrays^{28,38}

Figure 3. Schematic Representation of Mutations Identified and Algorithm for the Clinical Interpretation of Genetic Findings in Titin



A, Schematic visualization of truncating (circle) and missense (triangle) variants identified in *TTN* gene in this study. B, Workflow for interpreting titin variants. Previously reported, disease-causing mutations in the *TTN* gene easily address the diagnosis toward a titinopathy. Identifying 2 truncating variants on both the

alleles results in a diagnosis of titinopathy. A single heterozygous protein truncating variant is not sufficient for a diagnosis of titinopathy. Missense variants can lead to a diagnosis of titinopathy only when sufficient evidence supporting their pathogenicity is obtained.

Table 2. Features of Titin-Related Skeletal Musical Disorders

Dominant Inheritance		Recessive Inheritance			
Disease		Disease			
HMERF	TMD	LGMD2J	Adult-onset distal myopathy	Proximal adult-onset rimmed vacuolar myopathy	Congenital or early onset titinopathies
Genetics		Genetics			
Heterozygous exon 344 mutations	Heterozygous exon 364 mutations	Homozygosity (mainly exon 364 mutations) ^a Compound heterozygosity (mainly exon 364 + truncating mutations) ^a		Compound heterozygosity (exon 364 + missense mutations)	Compound heterozygosity (mainly truncating variants)
Key Point(s)		Key Point(s)			
Respiratory muscle weakness; "necklace" cytoplasmic bodies and myofibrillar changes in muscle biopsies	Degeneration of the muscles of the anterior lower legs starting in the anterior tibial muscle	Slowly progressive fatty degeneration (preserved muscles can be found in young patients)	Severe degeneration of tibialis anterior and soleus (unusual in TMD)	Prominent quadriceps and soleus involvement (sparing of tibial muscle); peculiar rimmed vacuoles in their muscle biopsies	Cardiac involvement often seen; sparing of extraocular muscles; early degeneration of semitendinosus, soleus, and peroneal; late involvement of the rectus femoris and vasti

^a The clinical phenotype depends on the specific exon 364 mutation.

should be used to assess the presence of large deletions or duplications³⁹ in unsolved cases. Western blotting is an effective strategy, although with well-recognized limitations. Inframe deletions, the skipping of inframe exons or truncating variants in exons not expressed in the adult muscles, and small size variations would still not be recognizable by a titin Western blot.

Several recent studies suggest that heterozygous titin truncating variants cause dominant dilated cardiomyopathy.^{40,41} However, a positional effect and an incomplete and age-dependent penetrance (probably related to other genetic or environmental factors) may explain the lack of any cardiac symptoms in some individuals with mono or biallelic PTVs (eg, patient V and VIII).⁴¹ A systematic follow-up to evaluate the cardiac status of such individuals, as well as their asymptomatic relatives who carry truncating variants, is highly recommended.

Missense Variants

The clinical significance of missense variants in *TTN* represents a major issue related to NGS investigation in the field of neuromuscular disorders.⁵ A WB analysis is not effective in the presence of missense variants, as demonstrated in cases IX and X. The evaluation of *TTN* missense variants should reflect the current genetic guidelines.⁴² A segregation analysis and/or in silico predictions can only suggest a pathogenic or a noncausative effect of a missense variant.⁴²

In the presence of monoallelic truncating variants, as well as of missense variants, the possible causative effect of mutations in genes other than titin has to be ruled out and the presence of the aforementioned key clinical points has to be assessed by deep phenotyping.

However, the definitive proof of pathogenicity for missense variants can only be established by functional tests, seg-

regation studies in very large families, and/or identifying unrelated patients or families with the same mutations. The interpretation of *TTN* missense variants may also benefit from the establishment of clinical and research consortia able to combine cohorts of patients into larger groups.⁴³

Limitations

Our study has limitations. First, we enrolled, in a multicenter study, patients with clinically and genetically heterogeneous conditions and specific clinical studies (magnetic resonance imaging or cardiac tests) were unavailable or not performed for some patients.

Second, we report missense variants with an unconfirmed causative role (cases IX and X). Although further studies are needed to attribute causality to missense changes, reporting possible causative variants is an effective strategy to improve consistency in the interpretation of molecular findings in titin. Ultimately, the proposed workflow is meant for interpreting titin variants in a mendelian disorder. The possible role of titin variants as modifiers or within a digenic or multigenic disease is not discussed here.

Conclusions

An increasing number of rare, ultrarare, and private variants in the titin gene is detected in any sequencing approach, and NGS has dramatically expanded the spectrum of skeletal muscle disorders associated with causative mutations in *TTN*.⁵ Our workflow results in a greater understanding and more consistent interpretation of titin variants by neurologists, pediatricians, and geneticists less familiar with the titin gene and titinopathies.

ARTICLE INFORMATION

Accepted for Publication: August 6, 2017.

Published Online: February 12, 2018.
doi:10.1001/jamaneurol.2017.4899

Author Affiliations: Folkhälsan Research Center, Medicum, University of Helsinki, Helsinki, Finland (Savarese, Vihola, Jonson, Evilä, Luque, Hackman, Udd); Dipartimento di Biochimica, Biofisica e Patologia Generale, Università degli Studi della Campania "Luigi Vanvitelli," Napoli, Italy (Savarese, Giugliano, Torella, Di Fruscio, Nigro); Telethon Institute of Genetics and Medicine, Pozzuoli, Italy (Savarese, Giugliano, Torella, Di Fruscio, Nigro); Neuromuscular Diseases and Neuroimmunology Unit, Institute for Research and Health Care Foundation Neurological Institute C. Besta, Milan, Italy (Maggi, Gibertini, Ruggieri, Antozzi, Pasanisi, Mora); Istituto di Neurologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli," Rome, Italy (Tasca); Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli Studi di Napoli "Federico II," Napoli, Italy (Ruggiero, Santoro); Neuromuscular Center, Dipartimento di Neuroscienze, Università di Padova, Padova, Italy (Bello, Pegoraro); Centro Dino Ferrari, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione Institute for Research and Health Care Ca' Granda, Ospedale Maggiore

Policlinico, Milan, Italy (Magri, Comi); Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium (Vanakker, Janssens); Neuromuscular Unit, Department of Neurosciences, Rita Levi Montalcini, University of Torino, Torino, Italy (Vercelli, Mongini); Pediatric Neurology and Neuromuscular Disorders Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal, and Child Health; University of Genoa, Istituto G. Gaslini, Genova, Italy (Fiorillo, Minetti); Clinica Moncucco, Lugano, Switzerland (Raimondi); Dipartimento di Medicina Sperimentale, Cardiomiologia e Genetica Medica, Università degli Studi della Campania "Luigi Vanvitelli," Napoli, Italy (Ergoli, Politano); Center of Myology and Neurodegenerative Disease, Istituto Giannina Gaslini, Genova, Italy (Bruno); Medicina Molecolare, Institute for Research and Health Care Fondazione Stella Maris, Pisa, Italy (Rubegni, Santorelli); Department of Pediatric Neurology, Catholic University and Nemo Roma Center for Neuromuscular Disorders, Rome, Italy (Pane, Mercuri); Fondazione Hospital S.Camillo Institute for Research and Health Care, Venezia, Italy (Angelini); Department of Neurology, Ghent University Hospital, Ghent, Belgium (De Blecker); Neuromuscular and Rare Disease Unit, Dipartimento di Neuroscienze, Università degli Studi di Milano, Fondazione Institute for Research and Health Care Ca' Granda, Ospedale Maggiore

Policlinico, Milano, Italy (Moggio); Neuromuscular Research Center, University of Tampere and Tampere University Hospital, Tampere, Finland (Udd).

Author Contributions: Dr Savarese had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Udd and Nigro contributed equally to this work.

Concept and design: Savarese, Maggi, Vihola, Jonson, Politano, Angelini, Comi, Hackman, Udd, Nigro.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Savarese, Maggi, Vihola, Jonson, Tasca, Bello, Giugliano, Di Fruscio, Vanakker, Rubegni, Santorelli, Udd, Nigro.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Savarese, Di Fruscio.

Obtained funding: Savarese, Angelini, Udd, Nigro.
Administrative, technical, or material support: Savarese, Vanakker, Vercelli, Janssens, Pasanisi, Raimondi, Politano, Moggio, Mongini, Comi, Mora, Udd.
Supervision: Savarese, Hackman, Udd, Nigro.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by Telethon Foundation, Telethon-Unione Italiana Lotta alla Distrofia Muscolare, Association Française contre les Myopathies, Orion Research Foundation, the Finnish Academy, and the Juselius Research Foundation.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Gaia Esposito, BSc, Manuela Dionisi, BSc, Francesco Musacchia, PhD, Margherita Mutarelli, PhD, and the Telethon Institute of Genetics and Medicine Next-generation Sequencing facility for the next-generation sequencing analyses and Anna Cuomo, BSc, and Rosalba Erpice, BSc, for the Sanger sequence analyses. We thank Jonathan Cole, BA, for linguistic editing of the article. We also thank the Italian Network of Congenital Myopathies, the Italian Network of Limb-Girdle Muscular Dystrophies, the Naples Human Mutation Gene Biobank, the Bank of muscle tissue, peripheral nerve, DNA and cell culture, the Bank of Cells, tissues and DNA, and the Neuromuscular Bank of Tissues and DNA samples, members of the Telethon Network of Genetic Biobanks and of Eurobiobank, as well as Kathleen Claes, PhD, Ghent University Hospital, for providing us with specimens. None of these individuals were compensated for their contributions.

REFERENCES

- Bang ML, Centner T, Fornoff F, et al. The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. *Circ Res*. 2001;89(11):1065-1072.
- Krüger M, Kötter S. Titin, a central mediator for hypertrophic signaling, exercise-induced mechanosignaling and skeletal muscle remodeling. *Front Physiol*. 2016;7:76.
- Gerull B. The rapidly evolving role of titin in cardiac physiology and cardiomyopathy. *Can J Cardiol*. 2015;31(11):1351-1359.
- Chauveau C, Rowell J, Ferreira A. A rising titan: TTN review and mutation update. *Hum Mutat*. 2014;35(9):1046-1059.
- Savarese M, Sarparanta J, Vihola A, Udd B, Hackman P. Increasing role of titin mutations in neuromuscular disorders. *J Neuromuscul Dis*. 2016;3(3):293-308.
- Charton K, Sarparanta J, Vihola A, et al. CAPN3-mediated processing of C-terminal titin replaced by pathological cleavage in titinopathy. *Hum Mol Genet*. 2015;24(13):3718-3731.
- Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy. late adult-onset distal myopathy in 66 Finnish patients. *Arch Neurol*. 1993;50(6):604-608.
- Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. *Am J Hum Genet*. 2002;71(3):492-500.
- Evilä A, Vihola A, Sarparanta J, et al. Atypical phenotypes in titinopathies explained by second titin mutations. *Ann Neurol*. 2014;75(2):230-240.
- Udd B, Kääriäinen H, Somer H. Muscular dystrophy with separate clinical phenotypes in a large family. *Muscle Nerve*. 1991;14(11):1050-1058.
- Hackman P, Marchand S, Sarparanta J, et al. Truncating mutations in C-terminal titin may cause more severe tibial muscular dystrophy (TMD). *Neuromuscul Disord*. 2008;18(12):922-928.
- Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. *Acta Myol*. 2014;33(1):1-12.
- Ceyhan-Birsoy O, Agrawal PB, Hidalgo C, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. *Neurology*. 2013;81(14):1205-1214.
- Fattori F, Maggi L, Bruno C, et al. Centronuclear myopathies: genotype-phenotype correlation and frequency of defined genetic forms in an Italian cohort. *J Neurol*. 2015;262(7):1728-1740.
- Carmignac V, Salih MA, Quijano-Roy S, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. *Ann Neurol*. 2007;61(4):340-351.
- Chauveau C, Bonnemann CG, Julien C, et al. Recessive TTN truncating mutations define novel forms of core myopathy with heart disease. *Hum Mol Genet*. 2014;23(4):980-991.
- De Cid R, Ben Yaou R, Roudaut C, et al. A new titinopathy: childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy. *Neurology*. 2015;85(24):2126-2135.
- Palmio J, Evilä A, Chapon F, et al. Hereditary myopathy with early respiratory failure: occurrence in various populations. *J Neurol Neurosurg Psychiatry*. 2014;85(3):345-353.
- Evilä A, Arumilli M, Udd B, Hackman P. Targeted next-generation sequencing assay for detection of mutations in primary myopathies. *Neuromuscul Disord*. 2016;26(1):7-15.
- Fernández-Marmiesse A, Carrascosa-Romero MC, Alfaro Ponce B, et al. Homozygous truncating mutation in prenatally expressed skeletal isoform of TTN gene results in arthrogyposis multiplex congenita and myopathy without cardiac involvement. *Neuromuscul Disord*. 2017;27(2):188-192.
- Thompson R, Straub V. Limb-girdle muscular dystrophies—international collaborations for translational research. *Nat Rev Neurol*. 2016;12(5):294-309.
- Nigro V, Savarese M. Next-generation sequencing approaches for the diagnosis of skeletal muscle disorders. *Curr Opin Neurol*. 2016;29(5):621-627.
- Helman G, Bonkowsky JL, Vanderver A. Neurologist comfort in the use of next-generation sequencing diagnostics: current state and future prospects. *JAMA Neurol*. 2016;73(6):621-622.
- Vasli N, Böhm J, Le Gras S, et al. Next-generation sequencing for molecular diagnosis of neuromuscular diseases. *Acta Neuropathol*. 2012;124(2):273-283.
- Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients. *Neurology*. 2016;87(1):71-76.
- Savarese M, Di Fruscio G, Mutarelli M, et al. MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples. *Acta Neuropathol Commun*. 2014;2:100.
- Mutarelli M, Marwah V, Rispoli R, et al. A community-based resource for automatic exome variant-calling and annotation in Mendelian disorders. *BMC Genomics*. 2014;15(suppl 3):S5.
- Piluso G, Dionisi M, Del Vecchio Blanco F, et al. Motor chip: a comparative genomic hybridization microarray for copy-number mutations in 245 neuromuscular disorders. *Clin Chem*. 2011;57(11):1584-1596.
- Gueux N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis*. 1997;18(15):2714-2723.
- Mrosek M, Labeit D, Witt S, et al. Molecular determinants for the recruitment of the ubiquitin-ligase MuRF-1 onto M-line titin. *FASEB J*. 2007;21(7):1383-1392.
- Tasca G, Ricci E, Monforte M, et al. Muscle imaging findings in GNE myopathy. *J Neurol*. 2012;259(7):1358-1365.
- Dubowitz VSC, Oldfors A. *Muscle Biopsy: A Practical Approach*. 4th ed. Philadelphia, PA: Saunders Ltd; 2013.
- Van den Bergh PYK, Bouquiaux O, Verellen C, et al. Tibial muscular dystrophy in a Belgian family. *Ann Neurol*. 2003;54(2):248-251.
- Evilä A, Palmio J, Vihola A, et al. Targeted next-generation sequencing reveals novel TTN mutations causing recessive distal titinopathy. *Mol Neurobiol*. 2016;54(9):7212-7223.
- Perić S, Glumac JN, Töpf A, et al. A novel recessive TTN founder variant is a common cause of distal myopathy in the Serbian population. *Eur J Hum Genet*. 2017;25(5):572-581.
- Robinson PN. Deep phenotyping for precision medicine. *Hum Mutat*. 2012;33(5):777-780.
- Tattini L, D'Aurizio R, Magi A. Detection of genomic structural variants from next-generation sequencing data. *Front Bioeng Biotechnol*. 2015;3:92.
- Savarese M, Piluso G, Orteschi D, et al. Enhancer chip: detecting human copy number variations in regulatory elements. *PLoS One*. 2012;7(12):e52264.
- Giugliano T, Fanin M, Savarese M, Piluso G, Angelini C, Nigro V. Identification of an intragenic deletion in the SGCB gene through a re-evaluation of negative next-generation sequencing results. *Neuromuscul Disord*. 2016;26(6):367-369.
- Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. *N Engl J Med*. 2012;366(7):619-628.
- Schafer S, de Marvao A, Adami E, et al. Titin-truncating variants affect heart function in disease cohorts and the general population. *Nat Genet*. 2017;49(1):46-53.
- Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424.
- Hackman P, Udd B, Bonnemann CG, Ferreira A; Titinopathy Database Consortium. 219th ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April-1 May 2016. *Neuromuscul Disord*. 2017;27(4):396-407.